Brigham and Women’s Cancer Center

• Lisa Hyde-Barrett

Background

Dana-Farber/Brigham and Women’s Cancer Center is one of the most prestigious and highly advanced cancer care centers in the US. As the affiliated teaching hospital of Harvard University, state-of-the-art facilities and world-class research create a dynamic atmosphere in which patients are able to receive the foremost treatments and technologies at their bedside.

Originally three separate hospitals, a 1980 merger created Brigham and Women’s Hospital to better serve the community. Since 1832, Brigham and Women’s Hospital has continually grown to accommodate the current and future needs of its community. The Dana-Farber/Brigham and Women’s Cancer Center was created to help its patients prevent and fight cancer. Dana-Farber/Brigham and Women’s Cancer Center created 12 specialized centers that are devoted to specific cancer types.

Brigham and Women’s Hospital and the Dana-Farber/Brigham and Women’s Cancer Center have consistently ranked among the top hospitals and cancer treatment facilities. The U.S. News and World Report ranks Brigham and Women’s Hospital as one of the top 20 hospitals in the US; it has 13 nationally ranked specialties. Dana-Farber/Brigham and Women’s Cancer Center is ranked No. 5 nationally.

Cancer Treatments

The Dana-Farber/Brigham and Women’s Cancer Center is situated to administer the latest research developments to provide improved cancer treatment options. Dana-Farber/Brigham and Women’s Cancer Center created the Thoracic Cancer Treatment Center at the Lowe Center for Thoracic Oncology to create an integrated research environment that provides the collaboration of laboratory scientists and physicians within clinical, translational, and prevention research studies surrounding lung cancer.

With regard to mesothelioma, Dana-Farber/Brigham and Women’s Cancer Center organizes teams of highly skilled staff to facilitate treatment in partnership with the Lowe Center for Thoracic Oncology to focus on the treatment of mesothelioma through the International Mesothelioma Program (IMP).

The International Mesothelioma Program treats the most mesothelioma patients in the world and is home to several of the world’s foremost mesothelioma specialists. Their expertise, research, and compassionate care have made the International Mesothelioma Program a coveted location for receiving treatment.

After referral or diagnosis by a primary care physician, a team of pathologists, radiologists, surgical and medical oncologists, thoracic surgeons, nurses, pharmacists, dietitians, and social workers will handle your case together. Dana-Farber/Brigham and Women’s Cancer Center has extensive expertise in the multi-modal treatment of mesothelioma. Several specific, innovative treatments are being researched, in addition to the comprehensive cancer treatments listed below. These include vaccine therapy, in vitro chemosensitivity testing, drug analysis, gene expression patterns, surgical techniques, and combinational treatment approaches to cure cancer.

David J. Sugarbaker, MD, is the founder of the International Mesothelioma Program and Disease Center Leader, Chief of Thoracic Surgery, and is the Richard E. Wilson Professor of Surgery at Harvard Medical School.

His extensive background in the surgical removal of lung cancer and expertise in mesothelioma make the Dana-Farber/Brigham and Women’s Cancer Center and International Mesothelioma Program an excellent location to seek high quality care and expertise. His research interests include the surgical treatment of lung cancer, congenital chest wall deformities, esophageal cancer and motility disorders.

Raphael Bueno, MD, is Associate Chief of Thoracic Surgery in the International Mesothelioma Program and is Professor of Surgery at Harvard Medical School. He is a surgical oncologist with a specialty in the removal of mesothelioma. His research interests include the surgical treatment of lung cancer, minimally invasive esophageal surgery, airway and endoscopic surgery, minimally invasive thoracic surgery, lung cancer and mesothelioma surgery, and multimodality therapy.

Scott J. Swanson, MD, is the Chief Surgical Officer and Disease Center Leader, Thoracic Oncology, and is Professor of Surgery at Harvard Medical School. He is the Director of the Minimally Invasive Thoracic Surgery Program. His research interests include the surgical treatment of lung cancer, thoracic oncology, minimally invasive surgery, esophageal cancer, sarcoma, and thymoma.

Radiation oncology, surgical oncology, clinical trials, chemotherapy, palliative care, state-of-the-art diagnostics and imaging services, pathology, genetic counseling, hormone therapy, biological therapy, complementary and alternative medicine, nutrition and physical therapy, support groups, and comprehensive and preventive care are all options in the Dana-Farber/Brigham and Women’s Cancer Center’s cancer treatment program.

Surgical and diagnostic innovations include pathology that is examined for gene expression patterns that lead to more effective and specialized treatment options. In-patient procedures are performed at Brigham and Women’s Hospital. Thornton and Naumes House, which is located across the street from Brigham and Women’s Hospital, provides housing for patients and families undergoing mesothelioma treatment.

Get more info about Mesothelioma Doctors & Hospitals.

Source: https://www.brighamandwomens.org/cancer-center